MorphoSys Finalizes Delisting from Frankfurt and Nasdaq Markets Following Novartis Acquisition

MorphoSys Finalizes Delisting from Frankfurt and Nasdaq Markets Following Novartis Acquisition

(IN BRIEF) MorphoSys AG has completed its voluntary delisting from the Frankfurt Stock Exchange and Nasdaq Global Market following its acquisition by Novartis. The delisting agreement, announced on June 20, 2024, and the subsequent delisting purchase offer by Novartis were key steps in this process. A resolution on the squeeze-out of minority shareholders will be discussed at the upcoming MorphoSys Annual General Meeting.

(PRESS RELEASE) PLANEGG/MUNICH, 5-Aug-2024 — /EuropaWire/ — MorphoSys AG has officially completed the voluntary delisting of its shares from the Frankfurt Stock Exchange and its American Depositary Shares (ADSs) from the Nasdaq Global Market. As of the end of trading on August 2, 2024, MorphoSys’ shares are no longer listed on the Frankfurt Stock Exchange. Additionally, the ADSs ceased trading on Nasdaq prior to the market opening on August 5, 2024.

The delisting follows the acquisition of MorphoSys by Novartis, finalized in May 2024. On June 20, 2024, MorphoSys entered into a delisting agreement with Novartis BidCo AG and Novartis AG. Subsequently, on July 4, 2024, Novartis initiated a public delisting purchase offer for all outstanding MorphoSys no-par value bearer shares.

Novartis BidCo Germany AG also announced plans to merge MorphoSys into Novartis by executing a squeeze-out of MorphoSys’ remaining minority shareholders. A resolution regarding this transfer, which includes cash compensation of €68.00 per share for minority shareholders, will be adopted at the MorphoSys Annual General Meeting on August 27, 2024.

Media Contact:

Thomas Biegi
Senior Vice President, Corporate Affairs
Tel.: +49 (0)89 / 899 27 26079
thomas.biegi@morphosys.com

Eamonn Nolan
Senior Director, Corporate Communications & Investor Relations
Tel: +1 617-548-9271
eamonn.nolan@morphosys.com

Investor Contacts:
Dr. Julia Neugebauer
Vice President, Global Investor Relations
Tel: +49 (0)89 / 899 27 179
julia.neugebauer@morphosys.com

Source: MorphoSys AG